Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL897058 | 0.81 | LPL (0.50) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL29424567 | 0.81 | LPL (0.50) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL21042445 | 0.81 | LIPG (0.50) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL17491867 | 0.80 | LPL (0.53) | LPLLIPGEGFRROCK1 | |
| SCHEMBL37395635 | 0.80 | LPL (0.41) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL6120636 | 0.80 | LPL (0.41) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL23949527 | 0.79 | LPL (0.33) | LPLLIPGP2RX7 | |
| SCHEMBL2355702 | 0.79 | LPL (0.40) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL257904 | 0.79 | LPL (0.40) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL22095433 | 0.79 | LPL (0.40) | LPLLIPGJAK2BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114126-B1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-10106544-B2 | 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-23 | — | — | US | disclosed |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| EP-3114126-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Actelion Pharmaceuticals Ltd (CH) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015132228-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106544-B2 | 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents | CCNI, H1-0, H1-3 | LPL 4816/4885LIPG 4789/4885JAK2 1633/4885 |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | CCNI, H1-0, H1-3 | LPL 4816/4885LIPG 4789/4885JAK2 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.